文献速递消化道肿瘤与早癌消化内镜

巴雷特食管定期监测与按需内镜的成本效益:巴雷特食管监测研究(BOSS)随机对照试验的经济学评价

Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2025-05-16

基于BOSS随机对照试验,比较每2年一次内镜监测与按需内镜的成本效益。每2年监测组总成本5309美元,按需组3182美元;每2年监测组QALY为8.647,按需组8.629。增量成本效果比为每获得1个QALY需115563美元,敏感性分析范围为94513至146272美元/QALY。结论认为每2至3年监测巴雷特食管不太可能具有成本效益。

要点

  • 每2年监测组总成本5309美元,按需内镜组3182美元。
  • 每2年监测组QALY为8.647,按需组为8.629,增量成本效果比115563美元/QALY。
  • 敏感性分析中增量成本效果比为94513至146272美元/QALY。

核心结论

  • 每2至3年监测巴雷特食管不太可能具有成本效益,指南在决定监测间隔时应考虑这一点。

研究设计与样本

  • 基于BOSS随机对照试验结果构建决策树模型,并进行成本效果分析,使用Markov模型将成本和结局外推至试验结束后10年,总时间跨度为22.8年。
  • 高级别不典型增生比例和QALY来自随机对照试验。

主要发现

  • 每2年监测组总成本为5309美元,按需内镜组为3182美元。
  • 每2年监测组总QALY为8.647,按需内镜组为8.629。
  • 与按需内镜相比,每2年监测每获得1个QALY需花费115563美元。
  • 在关于按需内镜组未检测到高级别不典型增生比例的敏感性分析中,最佳情形下增量成本效果比为94513美元/QALY,最差情形下为146272美元/QALY。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Barrett's Oesophagus Surveillance Study (BOSS) was the first randomized study of surveillance. This study reports the costs and quality of life outcomes from the BOSS trial and models the outcomes and cost-effectiveness of surveillance beyond the follow-up period of the BOSS study. This trial showed similar stages and rates of esophageal cancer in both arms, but the regular surveillance arm did identify more high-grade dysplasia after a median of 12.8 years follow-up. METHODS: We used a decision tree model based on results from BOSS to conduct a cost-effectiveness analysis of costs and quality-adjusted life years (QALYs). A Markov model was used to extrapolate costs and outcomes over a further 10 years after the trial had ended, representing a 22.8-year time horizon. The proportion with high-grade dysplasia and QALYs was derived from the randomized trial. RESULTS: The total costs associated with 2-yearly surveillance was $5309 vs $3182 in the at-need arm. Total QALYs in the 2-yearly endoscopy arm were 8.647 compared with 8.629 in the at-need arm. Compared with at-need endoscopy, 2-yearly surveillance costs $115,563/QALY gained. In the sensitivity analyses around assumptions on the proportion of high-grade dysplasia that is undetected in the at-need endoscopy arm, surveillance had an incremental cost effectiveness ratio of $94,513/QALY for the best-case and $146,272/QALY for the worst-case scenario. CONCLUSION: Barrett's esophagus surveillance every 2 to 3 years is unlikely to be a cost-effective strategy. Guidelines should take this into account when deciding surveillance intervals.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Deidda M, Old O, Jankowski J, et al. Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial. Gastroenterology. 2025. PMID: 40383306. doi:10.1053/j.gastro.2025.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。